Japan’s Optometry Device Maker Nidek Invests In Biopharma Ventures
This article was originally published in PharmAsia News
Japan Science and Technology Agency announced the establishment of Bioresource Application Institute. With a capital of ¥200 million ($2.0 million), BRA Institute is funded by Aichi, Japan-based ophthalmology and optometry device maker Nidek and Kitasato University professor Noruo Sakuragawa. The new company will utilize Sakuragawa's research on amniotic cells, which found a site population cell with stem-cell functions; the cell is expected to be used in gene therapy and to treat infertility. (Click here for more - Japanese language
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.